The airway epithelium is no longer understood as a passive wall. The panel traces how a barrier is now thought of as an immune organ, and what that shift means for severe asthma.
Back
The Evolving Role of Biologics and TSLP Inhibition in Severe Asthma and Upper Airway Disease
Expert pulmonologists and an allergist examine the evolving understanding of severe asthma and unified airway disease, including epithelial barrier dysfunction, epithelium-driven inflammation, and the upstream role of TSLP across diverse phenotypes. The panel reviews biomarkers, biologic selection, remission, and how integrated assessment and individualized strategies optimize outcomes in coexisting upper airway disease.
The Evolving Role of Biologics and TSLP Inhibition in Severe Asthma and Upper Airway Disease
Episodes
All
All
One cytokine sits above the rest. Dr. Hanania explains why TSLP earns the label of master regulator, and why blocking it reaches inflammation that current therapies cannot.
Advertisement
Advertisement
Trending on HCPLive
1
Why Povorcitinib's JAK1 Mechanism Matters for HS, With Martina Porter, MD
2
Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD
3
Defining On-Treatment Remission in Psoriasis and PsA
4
CHEST Guideline 2026: 13 Recommendations for Non-CF Bronchiectasis
5